Professional
Added to YB: 2024-09-10
Pitch date: 2024-09-10
AADI [neutral]
Whitehawk Therapeutics, Inc.
+32.58%
current return
Author Info
Special Situation Investments focuses on event-driven trades and low risk arbitrage opportunities with short term catalysts. Sign up for the newsletter.
Company Info
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments.
Market Cap
$100.9M
Pitch Price
$1.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
0.57
P/E
-6.90
EV/Sales
-4.29
Sector
Biotechnology
Category
special_situation
Aadi Bioscience: Worth Watching Amid Strategic Review and Net Cash Play
AADI (high uncertainly, but watching closely): Busted biopharma trading 10% below net cash. Failed Phase 2, 80% R&D layoffs. Commercialized PEComa drug (100-300 patients, $25M sales) up for sale. Strategic review ongoing. 40% insider ownership. Drug value est. 1-1.5x sales. $9M est. quarterly cash burn.
Read full article (2 min)